219 related articles for article (PubMed ID: 27060155)
1. A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort.
Terry KL; Schock H; Fortner RT; Hüsing A; Fichorova RN; Yamamoto HS; Vitonis AF; Johnson T; Overvad K; Tjønneland A; Boutron-Ruault MC; Mesrine S; Severi G; Dossus L; Rinaldi S; Boeing H; Benetou V; Lagiou P; Trichopoulou A; Krogh V; Kuhn E; Panico S; Bueno-de-Mesquita HB; Onland-Moret NC; Peeters PH; Gram IT; Weiderpass E; Duell EJ; Sanchez MJ; Ardanaz E; Etxezarreta N; Navarro C; Idahl A; Lundin E; Jirström K; Manjer J; Wareham NJ; Khaw KT; Byrne KS; Travis RC; Gunter MJ; Merritt MA; Riboli E; Cramer DW; Kaaks R
Clin Cancer Res; 2016 Sep; 22(18):4664-75. PubMed ID: 27060155
[TBL] [Abstract][Full Text] [Related]
2. Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort.
Fortner RT; Vitonis AF; Schock H; Hüsing A; Johnson T; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Benetou V; La Vecchia C; Palli D; Sieri S; Tumino R; Matullo G; Mattiello A; Onland-Moret NC; Peeters PH; Weiderpass E; Gram IT; Jareid M; Quirós JR; Duell EJ; Sánchez MJ; Chirlaque MD; Ardanaz E; Larrañaga N; Nodin B; Brändstedt J; Idahl A; Khaw KT; Allen N; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Cramer DW; Kaaks R; Terry KL
J Ovarian Res; 2017 Mar; 10(1):20. PubMed ID: 28320479
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
Fortner RT; Schock H; Le Cornet C; Hüsing A; Vitonis AF; Johnson TS; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Papatesta EM; La Vecchia C; Palli D; Sieri S; Tumino R; Sacerdote C; Mattiello A; Onland-Moret NC; Peeters PH; Bueno-de-Mesquita HBA; Weiderpass E; Quirós JR; Duell EJ; Sánchez MJ; Navarro C; Ardanaz E; Larrañaga N; Nodin B; Jirström K; Idahl A; Lundin E; Khaw KT; Travis RC; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Terry KL; Cramer DW; Kaaks R
Int J Cancer; 2018 Apr; 142(7):1355-1360. PubMed ID: 29159934
[TBL] [Abstract][Full Text] [Related]
4. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer.
Mukama T; Fortner RT; Katzke V; Hynes LC; Petrera A; Hauck SM; Johnson T; Schulze M; Schiborn C; Rostgaard-Hansen AL; Tjønneland A; Overvad K; Pérez MJS; Crous-Bou M; Chirlaque MD; Amiano P; Ardanaz E; Watts EL; Travis RC; Sacerdote C; Grioni S; Masala G; Signoriello S; Tumino R; Gram IT; Sandanger TM; Sartor H; Lundin E; Idahl A; Heath AK; Dossus L; Weiderpass E; Kaaks R
Br J Cancer; 2022 May; 126(9):1301-1309. PubMed ID: 35031764
[TBL] [Abstract][Full Text] [Related]
6. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
[TBL] [Abstract][Full Text] [Related]
7. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.
Kaaks R; Fortner RT; Hüsing A; Barrdahl M; Hopper M; Johnson T; Tjønneland A; Hansen L; Overvad K; Fournier A; Boutron-Ruault MC; Kvaskoff M; Dossus L; Johansson M; Boeing H; Trichopoulou A; Benetou V; La Vecchia C; Sieri S; Mattiello A; Palli D; Tumino R; Matullo G; Onland-Moret NC; Gram IT; Weiderpass E; Sánchez MJ; Navarro Sanchez C; Duell EJ; Ardanaz E; Larranaga N; Lundin E; Idahl A; Jirström K; Nodin B; Travis RC; Riboli E; Merritt M; Aune D; Terry K; Cramer DW; Anderson KS
Int J Cancer; 2018 Aug; 143(3):515-526. PubMed ID: 29473162
[TBL] [Abstract][Full Text] [Related]
9. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
11. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
Han C; Bellone S; Siegel ER; Altwerger G; Menderes G; Bonazzoli E; Egawa-Takata T; Pettinella F; Bianchi A; Riccio F; Zammataro L; Yadav G; Marto JA; Penet MF; Levine DA; Drapkin R; Patel A; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2018 Jun; 149(3):585-591. PubMed ID: 29572027
[TBL] [Abstract][Full Text] [Related]
12. Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer.
Simmons AR; Clarke CH; Badgwell DB; Lu Z; Sokoll LJ; Lu KH; Zhang Z; Bast RC; Skates SJ
Int J Gynecol Cancer; 2016 Jul; 26(6):1070-7. PubMed ID: 27206285
[TBL] [Abstract][Full Text] [Related]
13. HE4 combined with CA125: favorable screening tool for ovarian cancer.
Ghasemi N; Ghobadzadeh S; Zahraei M; Mohammadpour H; Bahrami S; Ganje MB; Rajabi S
Med Oncol; 2014 Jan; 31(1):808. PubMed ID: 24323399
[TBL] [Abstract][Full Text] [Related]
14. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
15. EPIC Early Detection of Ovarian Cancer.
Skates SJ
Clin Cancer Res; 2016 Sep; 22(18):4542-4. PubMed ID: 27418634
[TBL] [Abstract][Full Text] [Related]
16. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay.
Horala A; Swiatly A; Matysiak J; Banach P; Nowak-Markwitz E; Kokot ZJ
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28075407
[TBL] [Abstract][Full Text] [Related]
19. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
20. HE4 as an Early Detection Biomarker of Epithelial Ovarian Cancer: Investigations in Prediagnostic Specimens From the Janus Serumbank.
Gislefoss RE; Langseth H; Bolstad N; Nustad K; Mørkrid L
Int J Gynecol Cancer; 2015 Nov; 25(9):1608-15. PubMed ID: 26501436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]